| Literature DB >> 35041996 |
Ibrahim Y Abdelgawad1, Kevin Agostinucci2, Beshay N Zordoky3.
Abstract
Cancer survivorship has remarkably improved over the past decades; nevertheless, cancer survivors are burdened with multiple health complications primarily caused by their cancer therapy. Therapy-induced senescence is recognized as a fundamental mechanism contributing to adverse health complications in cancer survivors. In this mini-review, we will discuss the recent literature describing the mechanisms of cancer therapy-induced senescence. We will focus on endothelial cell senescence since it has been shown to be a key player in numerous cardiovascular complications. We will also discuss novel senotherapeutic approaches that have the potential to combat therapy-induced endothelial cell senescence.Entities:
Keywords: Anthracyclines; Cancer therapy; Cardio-oncology; Endothelial cells; Radiation; Senescence
Mesh:
Substances:
Year: 2022 PMID: 35041996 PMCID: PMC8844223 DOI: 10.1016/j.bbadis.2022.166352
Source DB: PubMed Journal: Biochim Biophys Acta Mol Basis Dis ISSN: 0925-4439 Impact factor: 5.187